A G6PD test is a blood test that measures the activity level of an enzyme called glucose-6-phosphate dehydrogenase in your red blood cells. This enzyme plays a critical role in protecting red blood cells from oxidative damage. When G6PD levels are too low, red blood cells become fragile and can rupture prematurely, a process called hemolysis. The test identifies whether you have G6PD deficiency, which affects an estimated 400 million people worldwide and is the most common enzyme deficiency in humans.
What G6PD Does in Your Body
Your cells constantly produce harmful byproducts called reactive oxygen species as part of normal metabolism. Think of them as chemical exhaust. G6PD is the enzyme responsible for generating the molecule your cells use to neutralize that exhaust. Without enough G6PD, your red blood cells lack this protective shield and are vulnerable to destruction when exposed to certain stressors.
Red blood cells are especially dependent on G6PD because, unlike most other cells, they have no backup systems for producing antioxidant protection. When oxidative stress overwhelms a G6PD-deficient red blood cell, the cell membrane breaks down and the cell is destroyed. This is what triggers the sudden episodes of anemia that characterize the condition.
Why Your Doctor Might Order It
A G6PD test is typically ordered in one of a few situations. The most common is when you’re showing signs of hemolytic anemia: unusual fatigue, pale or yellowed skin, rapid heart rate, shortness of breath, or dark or yellow-orange urine. These symptoms suggest your red blood cells are being destroyed faster than your body can replace them.
Newborns may also be tested if they develop jaundice that doesn’t resolve within two weeks or if there’s a family history of G6PD deficiency. Neonatal jaundice caused by G6PD deficiency can be severe and requires identification early.
The test is also ordered before prescribing certain medications known to trigger hemolytic crises in people with the deficiency. High-risk drugs include primaquine and tafenoquine (both antimalarials), dapsone, rasburicase, and phenazopyridine. Medium-risk medications include nitrofurantoin, a common antibiotic for urinary tract infections. If you’re G6PD-deficient and take one of these without knowing, you could experience a serious episode of red blood cell destruction.
How the Test Works
The test itself is a simple blood draw. What happens in the lab, though, varies depending on the type of test ordered. There are two main approaches: qualitative and quantitative.
A qualitative test is a screening tool. The most common version is the fluorescent spot test, which gives a yes-or-no answer about whether G6PD activity is severely low. It works well for catching pronounced deficiency but struggles to identify people with intermediate enzyme levels, particularly women who carry one copy of the altered gene.
A quantitative test measures the exact level of enzyme activity in your blood, typically reported in units per gram of hemoglobin. This gives a more precise picture and can detect mild or moderate deficiency that a screening test might miss. Normal reference ranges generally fall between about 11 and 20 U/g Hb for men and 12 and 23 U/g Hb for women, though ranges can vary by lab.
Timing Matters for Accuracy
One important detail that catches many people off guard: if you’re tested during or right after a hemolytic episode, your results may come back falsely normal. This happens because the oldest, most enzyme-deficient red blood cells are the first to be destroyed. The surviving cells and the new cells your body rushes to produce actually have higher-than-usual G6PD levels, masking the underlying deficiency. If your doctor suspects G6PD deficiency but the initial test is normal and you were recently symptomatic, the test should be repeated several weeks later.
Why Males Are More Commonly Affected
G6PD deficiency is inherited through the X chromosome. Males have only one X chromosome, so a single altered copy of the G6PD gene is enough to cause deficiency. Females have two X chromosomes, which often means one normal copy can compensate for one altered copy.
However, the picture for females is more complicated than it might seem. Early in development, each cell randomly shuts down one of its two X chromosomes. If the chromosome carrying the normal gene gets shut off in a disproportionate number of cells (a process called skewed X-inactivation), a woman can end up with G6PD deficiency just as severe as a man’s. Research shows this skewed pattern is common among women who carry the altered gene. This is also why qualitative screening tests sometimes miss female carriers: their enzyme activity can fall in an ambiguous middle range.
What Triggers a Hemolytic Episode
Most people with G6PD deficiency feel perfectly fine day to day. Problems arise when something overwhelms the limited antioxidant capacity of their red blood cells. The major triggers fall into a few categories.
- Fava beans: These contain compounds called vicine and convicine, which break down into potent oxidizing agents in your body. In someone with G6PD deficiency, these compounds directly damage red blood cell membranes. The reaction is severe enough that it has its own name: favism. Even inhaling pollen from fava plants can trigger it.
- Infections: Both viral and bacterial infections place oxidative stress on the body and can set off red blood cell destruction in G6PD-deficient individuals.
- Medications: Beyond the high-risk drugs mentioned earlier, certain common over-the-counter medications like ibuprofen and aspirin have also been identified as potential triggers.
Understanding Your Results
The World Health Organization classifies G6PD variants into categories based on how much enzyme activity remains and what symptoms occur. Class A variants have less than 20% of normal enzyme activity and cause chronic, ongoing hemolytic anemia, meaning red blood cells are being destroyed even without a specific trigger. Class B variants have less than 45% of normal activity and cause episodes of hemolytic anemia only when triggered by infections, medications, or fava beans. Class C variants retain more than 60% of normal activity and don’t cause hemolysis.
If your test shows you’re deficient, management centers on avoidance. Knowing your status lets you steer clear of the specific medications, foods, and situations that could trigger an episode. Most people with G6PD deficiency live completely normal lives once they know what to avoid. Hemolytic episodes, when they do happen, are usually self-limiting: once the trigger is removed, your body replaces the destroyed red blood cells within a few weeks. Severe episodes can occasionally require a blood transfusion, but this is uncommon.
If you have a family history of G6PD deficiency or belong to a population where it’s common (people of African, Mediterranean, Middle Eastern, or Southeast Asian descent), testing can be valuable even before symptoms appear, especially before starting any medication on the risk list.